Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia

N Awano, T Ryu, N Yoshimura, M Takazoe… - Internal …, 2011 - jstage.jst.go.jp
N Awano, T Ryu, N Yoshimura, M Takazoe, S Kitamura, M Tanaka
Internal Medicine, 2011jstage.jst.go.jp
A 23-year-old female was diagnosed as having simultaneous ulcerative colitis (UC) relapse
and hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) without FIP1L1-
platelet-derived growth factor receptor alpha (PDGFRA)(F/P) fusion gene. Pathological
findings of colon specimens were compatible with UC, however, focal severe infiltration of
eosinophils was observed in the rectum, which is unusual in UC, suggesting eosinophil-
mediated organ damage. Although imatinib mesylate (IM) is usually ineffective for the …
Abstract
A 23-year-old female was diagnosed as having simultaneous ulcerative colitis (UC) relapse and hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) without FIP1L1-platelet-derived growth factor receptor alpha (PDGFRA)(F/P) fusion gene. Pathological findings of colon specimens were compatible with UC, however, focal severe infiltration of eosinophils was observed in the rectum, which is unusual in UC, suggesting eosinophil-mediated organ damage. Although imatinib mesylate (IM) is usually ineffective for the treatment of HES/CEL with negative-F/P fusion gene, in the present case it led to the remission of HES/CEL and UC at a higher drug dosage level (400 mg/day). That suggested the presence of unknown tyrosine kinase abnormalities not yet categorized.
jstage.jst.go.jp